U.S. flag An official website of the United States government
  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. Development Resources
  5. Eravacycline – Injection Products
  1. Development Resources

Eravacycline – Injection Products

FDA-Identified Interpretive Criteria

 

Minimum Inhibitory
Concentrations

(mcg/mL)

Disk Diffusion
(zone diameter in mm)

Pathogen

S

I

R

S

I

R

Enterobacteriaceaea

≤0.5

-

-

≥15

-

-

Staphylococcus aureus

≤0.06

-

-

-

-

-

Enterococcus faecalis and
Enterococcus faecium

≤0.06

-

-

-

-

-

Streptococcus anginosus groupb

≤0.06

-

-

-

-

-

Anaerobesc

≤0.5

-

-

-

-

-

S=Susceptible; I = Intermediate; R = Resistant
For disk diffusion, use paper disks impregnated with 20 mcg eravacycline

a Clinical efficacy was shown for Citrobacter freundii, Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumonia.
b Clinical efficacy was shown for S. anginosus, S. constellatus, S. intermedius.
c Clinical efficacy was shown for Clostridium perfringens, Parabacteroides distasonis, Bacteroides caccae, Bacteroides fragilis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus.